

ARE WE PREPARED FOR PrEP? THE CHALLENGES OF IMPLEMENTING PROVEN BIOMEDICAL PREVENTION TECHNOLOGIES

IAS Industry Liaison Forum, 8am-10am, Sunday 22 July 2007, Parkside Ballroom B, Sydney Convention and Exhibition Centre, Darling Drive, Darling Harbour, Sydney



OVER 4 MILLION NEW HIV INFECTIONS OCCUR EVERY YEAR.
OVER 90% OF THESE ARE ACQUIRED IN DEVELOPING COUNTRIES.

Pre-exposure prophylaxis (PrEP) involving antiretroviral agents demonstrate great potential in reducing HIV transmission.

However, even if proven effective, the challenges of delivering PrEP remain formidable. Informed policy response, effective communication and advocacy as well as collaborations with potential funders will be paramount in the successful implementation of PrEP.

Programme Chairs

Elly Katabira
IAS-ILF Co-Chair and Makerere University,
Uganda

Joep Lange
IAS ILF Co-Chair and AMC Center for
Poverty-related Communicable Diseases, the
Netherlands

Event Organiser

Yasmin Halima, Senior Consultant,
International AIDS Society, Switzerland

Programme

8.00am **Welcome, introductions and programme objectives**
Elly Katabira

8.10am **What is the status of our preparation for PrEP implementation?**
Dawn Smith, US Centers for Disease Control and Prevention, USA

8.25am **How much could PrEP help? Modeling potential impact on the epidemic**
Sally Blower, University of California Los Angeles, USA

8.40am **Lessons learned from ARV rollout programmes**
Sheila Tlou, Ministry of Health, Botswana

9.00am **Discussion** facilitated by Joep Lange

9.15am **Roles and responsibilities in PrEP implementation**
Panel discussion facilitated by Pedro Cahn, IAS President and Huesped Fundación, Argentina

Discussants

Donor perspectives: Renee Ridzon, Bill & Melinda Gates Foundation, USA

Normative guidelines: Cate Hankins, UNAIDS

Civil society perspectives: Morenike Ukpong, Nigeria HIV Vaccine and Microbicide Advocacy Group, Nigeria

Industry responsibilities: Wim Parys, Tibotec, Belgium

10.00am Meeting close